Furthermore, Riess et al33 used the experimental cyclin‐dependent kinase inhibitor Dinaciclib to suppress IDO activity, thus reducing tryptophan metabolism via the kynurenine pathway in HNSCC cell lines, whilst chemotherapeutics tend to activate this pathway. The gene discussed is IDO1; the disease is head and neck squamous cell carcinoma.